Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancermetastatictherapyrecurrentsquamous
  Phrases that lowered it: safety ofclinicalefficacypatientsinvestigator
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Design: single group (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Keywords listed: 14 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Minimum age: 14 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® NCT02423863 · started 2015 · scored riskier than 80% of active trials completed
• Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma NCT00880867 · started 2009 · scored riskier than 98% of active trials terminated
• A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma NCT01410968 · started 2011 · scored riskier than 89% of active trials completed
• HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors NCT02536469 · started 2015 · scored riskier than 33% of active trials completed
• Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 NCT03721679 · started 2018 · scored riskier than 81% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.